RespireRx Pharmaceuticals Inc (fka RSPI)

[neuroinv]

I havent been a big fan of Remoxy. The Durect time release technology should reduce abuse appeal by making the drug-uptake curve less steep (i.e. attenuating the 'rush'). It's not specifically intended to avoid RD--maybe Enemem would know whether titrating the rate of opioid uptake would affect likelihood of RD. My guess is--not enough to make a real difference.

NeuroInvestment